Marker Therapeutics (NASDAQ:MRKR) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Marker Therapeutics (NASDAQ:MRKR) from a hold rating to a sell rating in a research report released on Sunday.

A number of other analysts have also commented on MRKR. Zacks Research raised Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Marker Therapeutics in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $10.25.

Marker Therapeutics Stock Performance

Shares of NASDAQ:MRKR opened at $1.29 on Friday. Marker Therapeutics has a 52-week low of $0.81 and a 52-week high of $5.95. The company has a market capitalization of $21.42 million, a PE ratio of -1.04 and a beta of 1.35. The company has a fifty day moving average of $1.00 and a 200-day moving average of $1.21.

Marker Therapeutics (NASDAQ:MRKR) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.57. The company had revenue of $1.23 million for the quarter, compared to the consensus estimate of $0.72 million. Marker Therapeutics had a negative return on equity of 92.35% and a negative net margin of 304.56%. On average, equities analysts forecast that Marker Therapeutics will post -0.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Marker Therapeutics

Hedge funds have recently made changes to their positions in the stock. Two Sigma Investments LP acquired a new stake in Marker Therapeutics during the 3rd quarter valued at approximately $33,000. Virtu Financial LLC bought a new stake in shares of Marker Therapeutics in the 3rd quarter valued at $25,000. Finally, Jane Street Group LLC bought a new stake in shares of Marker Therapeutics in the 2nd quarter valued at $33,000. 22.39% of the stock is currently owned by institutional investors.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.